📊 LNAI Key Takeaways
Is Lunai Bioworks Inc. (LNAI) a Good Investment?
Lunai Bioworks faces imminent solvency crisis with negative stockholders equity of -$9.6M, indicating liabilities exceed assets. The company burns $3.4M in operating cash annually against nearly zero revenue ($20.9K), providing less than one year of runway from remaining cash reserves. With a current ratio of 0.19x and no meaningful revenue generation, going-concern risk is critical.
Fundamentals indicate acute financial distress: de minimis revenue with massive operating losses, negative equity, and a critical liquidity position (0.03x current ratio, ~$0.5M cash vs. -$2.4M OCF). Reported net income appears driven by non-operating/one-time items, masking weak core operations. Absent immediate financing and a credible path to sustainable revenue, dilution or restructuring risk dominates.
Lunai Bioworks Inc. Key Strengths (LNAI)
- Retains $3.2M in cash providing short-term liquidity runway
- Minimal long-term debt ($540K) reduces leverage obligations
- Low ongoing capital requirements suggest reduced burn from non-essential spending
- Asset-light model with minimal capex needs
- Low absolute long-term debt balance
- Recent net profit from non-operating items provides temporary cushion
LNAI Stock Risks: Lunai Bioworks Inc. Investment Risks
- Negative stockholders equity of -$9.6M indicates technical insolvency and balance sheet collapse
- Operating cash burn of -$3.4M annually with <1 year cash runway creates urgent refinancing/shutdown timeline
- Revenue collapse to $20.9K reveals failed commercialization with no viable business model or product-market traction
- Current ratio of 0.19x signals inability to meet current liabilities, creating imminent liquidity crisis
- Zero insider Form 4 activity over 90 days suggests absent insider confidence in survival prospects
- Going concern risk elevated; company likely requires dilutive emergency financing or restructuring
- Severe liquidity shortfall and going-concern risk
- Negative shareholders’ equity and high dependence on external financing/dilution
- Collapsing revenue and deeply negative operating margins
Key Metrics to Watch
- Cash balance depletion rate and remaining runway months
- Any financing announcements or dilutive offerings
- Revenue inflection or shutdown/merger announcements
- Cash runway (cash vs. quarterly operating cash burn)
- Current ratio and net working capital
Lunai Bioworks Inc. (LNAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
LNAI Profit Margin, ROE & Profitability Analysis
LNAI vs Healthcare Sector: How Lunai Bioworks Inc. Compares
How Lunai Bioworks Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lunai Bioworks Inc. Stock Overvalued? LNAI Valuation Analysis 2026
Based on fundamental analysis, Lunai Bioworks Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lunai Bioworks Inc. Balance Sheet: LNAI Debt, Cash & Liquidity
LNAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lunai Bioworks Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.91 indicates the company is currently unprofitable.
LNAI Revenue Growth, EPS Growth & YoY Performance
LNAI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $20.9K | $189.2K | $0.00 |
| Q3 2018 | N/A | $15.0K | N/A |
| Q3 2017 | $42.5K | -$207.6K | N/A |
| Q2 2017 | $42.5K | -$421.8K | N/A |
| Q3 2016 | $42.5K | -$207.6K | N/A |
| Q2 2016 | $42.5K | -$421.8K | N/A |
| Q3 2014 | $925 | -$371.5K | N/A |
| Q2 2014 | $31.6K | -$343.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lunai Bioworks Inc. Dividends, Buybacks & Capital Allocation
LNAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lunai Bioworks Inc. (CIK: 0001527728)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNAI
What is the AI rating for LNAI?
Lunai Bioworks Inc. (LNAI) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNAI's key strengths?
Claude: Retains $3.2M in cash providing short-term liquidity runway. Minimal long-term debt ($540K) reduces leverage obligations. ChatGPT: Asset-light model with minimal capex needs. Low absolute long-term debt balance.
What are the risks of investing in LNAI?
Claude: Negative stockholders equity of -$9.6M indicates technical insolvency and balance sheet collapse. Operating cash burn of -$3.4M annually with <1 year cash runway creates urgent refinancing/shutdown timeline. ChatGPT: Severe liquidity shortfall and going-concern risk. Negative shareholders’ equity and high dependence on external financing/dilution.
What is LNAI's revenue and growth?
Lunai Bioworks Inc. reported revenue of $20.9K.
Does LNAI pay dividends?
Lunai Bioworks Inc. does not currently pay dividends.
Where can I find LNAI SEC filings?
Official SEC filings for Lunai Bioworks Inc. (CIK: 0001527728) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNAI's EPS?
Lunai Bioworks Inc. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LNAI's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lunai Bioworks Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LNAI stock overvalued or undervalued?
Valuation metrics for LNAI: ROE of N/A (sector avg: 15%), net margin of -7,409.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LNAI's AI grade for 2026?
Our dual AI analysis gives Lunai Bioworks Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LNAI's free cash flow?
Lunai Bioworks Inc.'s operating cash flow is $-3.4M, with capital expenditures of $1.2K. FCF margin is -16,466.5%.
How does LNAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7,409.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.19 (avg: 2).